Navigation Links
Advanced Circulatory Systems Receives $1.5 Million From NIH for Study of Cardiac Arrest Resuscitation Techniques
Date:10/13/2008

Oshkosh is one of six sites included in national study

Study needed because of low cardiac arrest survival rates

OSHKOSH, Wis., Oct. 13 /PRNewswire/ -- Advanced Circulatory Systems, Inc. (http://www.advancedcirculatory.com) announced today that it has received an additional $1.5 million in funding from the National Institutes of Health (NIH) to continue a study testing two devices used in combination on those who experience cardiac arrest outside a hospital. Oshkosh is one of six sites included in the national study.

The study is needed because of the dismally low survival rates for cardiac arrest; the national average for surviving such a cardiac arrest that occurs outside a hospital setting is only one in twenty.

The NIH funding will be used to increase enrollment in the six-site study. The study involves the testing of the ResQPump(R) an active compression/decompression device, in combination with the ResQPOD(R), a device used to increase blood flow to the heart and brain during CPR. The ResQPOD, an impedance threshold device proven to increase circulation, has previously received clearance from the FDA and is in use at more than 1,100 customer sites in the US. The current NIH funded study is the first randomized study in the US to assess results of the ResQPump and ResQPOD used together and comparing results when CPR is performed without these devices. The ResQPump has been tested and is currently in use in Europe. Both devices are designed and manufactured by Advanced Circulatory Systems of Minneapolis, MN.

The six sites involved in the study include Minneapolis, MN; St. Paul, MN; Whatcom County, WA; Oshkosh, WI; suburban Detroit including parts of Oakland and Macomb counties, MI; and Livingston County, MI which includes the city of Ann Arbor.

The use of new technologies as well as improved CPR procedures as recommended by the American Hear
'/>"/>

SOURCE Advanced Circulatory Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
3. Advanced Age No Bar to Liver Transplant
4. Oncologists are critical in managing psychiatric disorders in patients with advanced cancer
5. Advanced technologies aim to transform the coaching of top athletes
6. Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel
7. Advanced Life Sciences Joins NASDAQ Capital Market
8. Experimental drug shows promise in advanced kidney cancer
9. TCS Healthcare Technologies Announces Full Integration of Case Management Adherence Guidelines into Acuity Advanced Care(TM) System
10. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... ,, KANSASCITY,Mo.,Nov.25/PRNewswire/--TheBa...tion,slargestmedicalcliniconDec.9-10,whenKansasCit...nsuredpeople. ,, "Thisfreecliniceventhasthepote...wodaysinsteadofjustoneandbeheldonweekdaysinsteadof...asCityFreeHealthClinicandpresidentoftheNationalAss...
(Date:11/25/2009)... ,, SILVERSPRING,Md.,Nov.25/PRNewswire-USNew...eFDA,sCenterforDrugEvaluationandResearch,titled"AD...A,"appearsintheNov.26,2009issueofTheNewEnglandJour.../cgi-bin/prnh/20090824/FDALOGO ) ,, Inthearticl...enaccesstopainmedicationforthosewhoneeditandmanagi...
(Date:11/25/2009)... , Researchers have found evidence of a statistic...moxifen among patients whose estrogen receptor (ER...on of ER-alpha; at serine-118 (ER-alpha S118-P), a... November 25 in the Journal of the National Cance...inomas are resistant to tamoxifen. Preclinical stu...
(Date:11/25/2009)... , Evaluation and treatme... Woodstock (Vocus) November 25, 2009 ...1N1 nasal vaccines and H1N1 vaccine shots at four ...nce another shipment of vaccine has arrived. The c...stal Lake and McHenry and will be open as follows:...
(Date:11/25/2009)... ,, ARLINGTON,Va.,Nov.25/PRNewswire-USNewswi...ew"PreventHealthCareFraudActof2009,"S.2128,whichis...ilabletopreventfraudinMedicare.Thebillwasintroduce...containsseveralprovisionstheAmericanAssociationfor...whichtheAssociationproposedtoCongressinFebruary.Th...
Breaking Medicine News(10 mins):Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...fically press photographers have been suspected of...picion was unveiled// by a health official belongi...of our working hypotheses. Bird flu can be transmi... across the country,' said the health official. ...
...study conducted by India and Canada which was carr... research institute reported// a decrease in the H...15 to 24 years suffering from HIV in the states of...h Indian states. The four states account for ...
...for the elders to slip into the past and reminisce...th, but psychologists warn// that such frequent re...with the present. This phenomenon becomes a p...peating boring old yarns, it is not a normal sympt...
...ria and Tuberculosis in most developing countries ...opean Union, UNAIDS, WHO and the Indian Government...strategy against the diseases. "These diseas...he diseases in various countries," Mr.Alexander Sp...
...VT) or clot formation is on the rise among patient...r Liam Smeeth, from the London School of Hygiene a...ook at whether infection could trigger DVT or pulm...he London team found those who had suffered either...
...S. health regulators, gave their nod to the first ...tion in heart transplant patients.// The drug, ... to prevent rejection of liver and kidney transpla...ants in the U.S. each year will now have a new opt...
Other Medicine News:Health News:Reminiscing Into The Past Makes You Dissatisfied With The Present 2Health News:DVT Risk Increased After Acute Infections 2
(Date:11/25/2009)...TheFDAgrantedtraditionalapprovalforINTELENCE®...ptaseinhibitor(NNRTI).INTELENCEistheonlyNNRTIspeci...swhoareexperiencingvirologicfailurewithHIV-1strain...ts.Thetraditionalapprovalisbasedon48-weekdatafromt...urrentlymarketedintheU.S.byTibotecTherapeutics,adi...
(Date:11/25/2009)...-RegadoBiosciences,aprivatelyheldcompanyleadingthe...olagents,announcedthatDavidMazzo,PhD,CEOandPreside...thCareConferenceattheNewYorkPalaceHotelinNewYorkCi...nTuesday,December1andwillincludeanoverviewoftheCom...ram,theanticoagulantsystem,REG1.Thehealthcareindus...
(Date:11/25/2009)...rstCall/--Abaxis,Inc.(Nasdaq: ABAX ),amedicalprodu...ystems,announcedtodaythatClintSeverson,chairmanand...perJaffrayHealthCareConferenceonWednesday,December...YorkPalaceHotelinNewYorkCity. ,, AboutAbaxis ...ebloodanalysissystemsforuseinanyveterinaryorhumanp...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Beckman Coulter Announces Third Quarter 2009 Results 5858 1Beckman Coulter Announces Third Quarter 2009 Results 5858 2Beckman Coulter Announces Third Quarter 2009 Results 5858 3Beckman Coulter Announces Third Quarter 2009 Results 5858 4Beckman Coulter Announces Third Quarter 2009 Results 5858 5Beckman Coulter Announces Third Quarter 2009 Results 5858 6Beckman Coulter Announces Third Quarter 2009 Results 5858 7Beckman Coulter Announces Third Quarter 2009 Results 5858 8Beckman Coulter Announces Third Quarter 2009 Results 5858 9Beckman Coulter Announces Third Quarter 2009 Results 5858 10Beckman Coulter Announces Third Quarter 2009 Results 5858 11Beckman Coulter Announces Third Quarter 2009 Results 5858 12Beckman Coulter Announces Third Quarter 2009 Results 5858 13Beckman Coulter Announces Third Quarter 2009 Results 5858 14Beckman Coulter Announces Third Quarter 2009 Results 5858 15Beckman Coulter Announces Third Quarter 2009 Results 5858 16Beckman Coulter Announces Third Quarter 2009 Results 5858 17Beckman Coulter Announces Third Quarter 2009 Results 5858 18Beckman Coulter Announces Third Quarter 2009 Results 5858 19Beckman Coulter Announces Third Quarter 2009 Results 5858 20Beckman Coulter Announces Third Quarter 2009 Results 5858 21Beckman Coulter Announces Third Quarter 2009 Results 5858 22Beckman Coulter Announces Third Quarter 2009 Results 5858 23Beckman Coulter Announces Third Quarter 2009 Results 5858 24Beckman Coulter Announces Third Quarter 2009 Results 5858 25Beckman Coulter Announces Third Quarter 2009 Results 5858 26Beckman Coulter Announces Third Quarter 2009 Results 5858 27Beckman Coulter Announces Third Quarter 2009 Results 5858 28Beckman Coulter Announces Third Quarter 2009 Results 5858 29Beckman Coulter Announces Third Quarter 2009 Results 5858 30Beckman Coulter Announces Third Quarter 2009 Results 5858 31Beckman Coulter Announces Third Quarter 2009 Results 5858 32Beckman Coulter Announces Third Quarter 2009 Results 5858 33Beckman Coulter Announces Third Quarter 2009 Results 5858 34Beckman Coulter Announces Third Quarter 2009 Results 5858 35Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 1Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 2Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 3Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 4Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 5Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 6Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 7Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 8BioCryst to Present at Oppenheimer Healthcare Conference 5852 1BioCryst to Present at Oppenheimer Healthcare Conference 5852 2
...t. 18 Forest,Laboratories (NYSE: FRX ) announced...duced a significant bronchodilatory response in 17...e IIa trial presented today at the,European Respir...1) (Logo: http://www.newscom.com/cgi-bin/prnh/20...that mean FEV1 and FVC values - important,measures...
... http://www.wilsoncenter.org/globalhealth , WASHI...e W. Bush called for a reauthorization of the Pres...hich is set to expire at the end,of fiscal year 20... the,initial 2003 commitment of $15 billion to $30...20, 2007, the Woodrow Wilson Center,s Global Healt...
Other Medicine Technology:Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 2Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 3Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 4Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 5Director's Forum: PEPFAR and the Global AIDS Response 2
...the user to quickly and accurately count bacteria ...unting or manual counting. An optional 1.5X auxili...gnification to 3.0X. The adjustable focusing rod a...ed. The lens also rotates a full 360 for ready acc...
...the user to quickly and accurately count bacteria ...unting or manual counting. An optional 1.5X auxili...gnification to 3.0X. The adjustable focusing rod a...ed. The lens also rotates a full 360 for ready acc...
Accucount 2000 (115V/60Hz)
Accucount 1000 (115V/60Hz)
Medicine Products: